SCHEMBL22010911

SCHEMBL22010911

COc1cccc(Oc2ccc(Br)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.67
MAOB P27338 2/20 0.59
MTNR1B P49286 8/20 0.54
MTNR1A P48039 6/20 0.54
LTA4H P09960 1/20 0.54
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
PGR P06401 3/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
MITF O75030 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
GFER P55789 1/20 0.50
KMT2A Q03164 1/20 0.50
NLRP1 Q9C000 1/20 0.50
NOD2 Q9HC29 1/20 0.50
ACHE P22303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31033289 1.00 SMN1; SMN2 (0.67) SMN1; SMN2MAOBMTNR1BMTNR1ALTA4H
SCHEMBL3843560 0.89 MAPT (0.60) SMN1; SMN2MAOBLTA4HMAPTMEN1
SCHEMBL10709191 0.89 SMN1; SMN2 (0.80) SMN1; SMN2MTNR1BMTNR1ALTA4HKDM4E
SCHEMBL3842372 0.89 MAPT (0.60) SMN1; SMN2MAOBLTA4HMAPTMEN1
SCHEMBL11049862 0.87 SMN1; SMN2 (0.77) SMN1; SMN2MTNR1BMTNR1ALTA4HKDM4E
SCHEMBL21984851 0.85 ABL1 (0.56) SMN1; SMN2MAOBLTA4H
SCHEMBL4608736 0.85 SMN1; SMN2 (0.73) SMN1; SMN2MTNR1BMTNR1ALTA4HKDM4E
SCHEMBL29929943 0.85 SMN1; SMN2 (0.72) SMN1; SMN2MAOBMTNR1BMTNR1ALTA4H
SCHEMBL30053231 0.85 SMN1; SMN2 (0.72) SMN1; SMN2MAOBMTNR1BMTNR1ALTA4H
SCHEMBL13167638 0.85 SMN1; SMN2 (0.72) SMN1; SMN2MAOBMTNR1BMTNR1ALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545672-B2 Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof DEBIOPHARM INTERNATIONAL S.A. (CH) 2026-02-10 US disclosed
EP-3880675-B1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF DEBIOPHARM INT SA (CH) 2024-11-06 EP disclosed
US-20230035837-A1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF DEBIOPHARM INTERNATIONAL S.A. (CH) 2023-02-02 US disclosed
EP-3880675-A1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF Debiopharm International SA (CH) 2021-09-22 EP disclosed
WO-2020099341-A1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF DEBIOPHARM INTERNATIONAL S.A. (CH) 2020-05-22 WO disclosed
WO-2020099341-A1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF DEBIOPHARM INTERNATIONAL S.A. (CH) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545672-B2 Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof MRPL21, EMG1, RRS1 SMN1; SMN2 2288/4885MAOB 2484/4885MTNR1B 1361/4885
US-20230035837-A1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF GMPS, GNE, GANC SMN1; SMN2 2528/4885MAOB 470/4885MTNR1B 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.